FDA Approves First-of-its-Kind Intentional Genomic Alteration in Line of Domestic Pigs for Both Human Food, Potential Therapeutic Uses
December 15, 2020 —
Today, the U.S. Food and Drug Administration approved a first-of-its-kind intentional genomic alteration (IGA) in a line of domestic pigs, referred to as GalSafe pigs, which may be used for food or human therapeutics. This is the first IGA in an animal that the FDA has approved for both human food consumption and as a source for potential therapeutic uses. The IGA in GalSafe pigs is intended to eliminate alpha-gal sugar on the surface of the pigs' cells. People with Alpha-gal syndrome (AGS) may have mild to severe allergic reactions to alpha-gal sugar found in red meat (e.g., beef, pork, and lamb). [Source: FDA 14 December 2020] Read more here.
- Next story: FDA Releases 2018 NARMS Integrated Summary and NARMS Now: Integrated Data Featuring Genomic Data and Predicted Resistance
- Next in category: Summary of Possible Multistate Enteric (Intestinal) Disease Outbreaks in 2017–2020
- Previous in category: Plan Guides Agency Efforts to Lead with Science in Tackling Foodborne Pathogens
- Previous story: FDA Releases Annual Summary Report on Antimicrobials Sold or Distributed in 2019 for Use in Food-Producing Animals